VolitionRx Limited (NYSE American: VNRX) is drawing attention to a mounting body of clinical and scientific evidence supporting its Nu.Q NETs assay as a biomarker for sepsis and other diseases associated with NETosis. The company also released an educational video featuring Critical Care Lead and Medical Consultant Dr. Andrew Retter to further elucidate the test’s potential.
Multiple studies have demonstrated that the Nu.Q H3.1 test can differentiate sepsis from non-infectious inflammation, correlate with disease severity, and provide strong prognostic value for outcomes including organ failure and mortality. Most of this research has been peer reviewed and published, with experts noting consistency across various countries and patient populations, according to the company.
VolitionRx believes its low-cost nucleosome quantification technology could help personalize patient care by identifying elevated H3.1 nucleosome levels as a treatable trait in sepsis management, potentially informing future therapeutic strategies. Sepsis remains a critical global health issue, and early, accurate diagnosis is key to improving patient outcomes.
The company’s Nu.Q NETs test measures nucleosomes, which are released during NETosis—a form of cell death associated with inflammation and infection. Elevated levels have been linked to sepsis severity and poor prognosis. The test’s ability to distinguish sepsis from other inflammatory conditions could reduce unnecessary antibiotic use and improve resource allocation in intensive care units.
VolitionRx is a multinational company focused on advancing epigenetics, aiming to save lives and improve outcomes through earlier detection and monitoring of diseases. Its research and development activities are based in Belgium, with an innovation lab in the U.S. and an office in London. The company develops simple, cost-effective blood tests for detecting and monitoring cancers and diseases associated with NETosis, such as sepsis.
For more information, visit the company’s website at https://volition.com/. The full press release is available at https://ibn.fm/2IH3m.
